NASDAQ · Drug Manufacturers - Specialty & Generic

RGC (RGC) Stock

$5.92 -0.84% NASDAQ: RGC Healthcare

Valuation

MetricValue
Price$5.92
Market Cap$2.93B
P/E Ratio120.34
P/B Ratio2635.00
P/S Ratio0.00
EPS (TTM)$-0.01
52-Week High$69.00
52-Week Low$4.83
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-54.81%
ROA-33.20%
ROCE-31.75%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.32
Current Ratio5.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-1.0M$-8.0M$-6.0M$-5.0M$-4.0M
Net Profit$-1.0M$-7.0M$-6.0M$-4.0M$-4.0M
EPS$0.00$-0.01$-0.01$-0.01$-0.01
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$0$18.0M$13.0M$8.0M$6.0M
Total Liabilities$4.0M$1.0M$1.0M$0$1.0M
Cash$0$6.0M$2.0M$3.0M$2.0M
Borrowings$4.0M$1.0M$0$0$1.0M

Latest News

Auditor Change Puts Regencell Bioscience Governance And Cash Runway In Focus Simply Wall St. · Apr 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-1.0M$-5.0M$-5.0M$-4.0M$-3.0M
Investing Cash Flow$0$-12.0M$0$5.0M$3.0M
Financing Cash Flow$0$22.0M$0$0$0
Net Cash Flow$0$6.0M$-5.0M$1.0M$-1.0M
Free Cash Flow$-1.0M$-6.0M$-5.0M$-4.0M$-3.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-27.08
EV / EBITDA-3920.13
FCF Yield0.00%
Quick Ratio1.42
Interest Coverage—
Return 1Y-56.51%
Return 3Y1029.55%
Return 5Y2368.97%

Ownership

Insiders Held88.38%
Institutions Held0.14%
Institutions Float Held1.16%
Institutional HolderSharesReport Date
Geode Capital Management, LLC415,5692026-03-31
GSA Capital Partners LLP31,5692026-03-31
Marex Group Plc31,6002026-03-31
Vident Advisory, LLC 29,5882026-03-31
Squarepoint Ops LLC26,6132026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABVXAbivax S.A. $136.94 +1.50% -24.37 $10.06B 0.00%
ATR $136.77 +2.10% 19.32 $8.73B 1.66%
AXSM $238.37 -1.09% 38.05 $12.27B 0.00%
CYTKCytokinetics, Incorporated $80.62 -0.15% -11.82 $10.03B 0.00%
GRFSGrifols, S.A. $7.27 -0.27% 14.60 $6.15B 1.24%

About RGC

RGC stock trades at $5.92 with a market capitalization of $2.93B. The stock is valued at a price-to-earnings (P/E) ratio of 120.34, price-to-book of 2635.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.83 and $69.00, and currently trades 91.4% below its 52-week high.

On profitability, RGC generates a return on equity (ROE) of -54.81%, return on capital employed of -31.75%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides